Literature DB >> 16943256

Identification of bombesin receptor subtype-specific ligands: effect of N-methyl scanning, truncation, substitution, and evaluation of putative reported selective ligands.

Samuel A Mantey1, Nieves Gonzalez, Michael Schumann, Tapas K Pradhan, Lin Shen, David H Coy, Robert T Jensen.   

Abstract

Mammalian bombesin (Bn) receptors include the gastrin-releasing peptide receptor, neuromedin B receptor, and bombesin receptor subtype 3 (BRS-3). These receptors are involved in a variety of physiological/pathologic processes, including thermoregulation, secretion, motility, chemotaxis, and mitogenic effects on both normal and malignant cells. Tumors frequently overexpress these receptors, and their presence is now used for imaging and receptor-mediated cytotoxicity. For these reasons, there is an increased need to develop synthetic, selective receptor subtype-specific ligands, especially agonists for these receptors. In this study, we used a number of strategies to identify useful receptor subtype-selective ligands, including synthesizing new analogs (N-methyl-substituted constrained analogs, truncations, and substitutions) in [d-Tyr(6),betaAla(11),Phe(13),Nle(14)]Bn(6-14), which has high affinity for all Bn receptors and is metabolically stable, as well as completely pharmacologically characterized analogs recently reported to be selective for these receptors in [Ca(2+)](i) assays. Affinities and potencies of each analog were determined for each human Bn receptor subtype. N-Methyl substitutions in positions 14, 12, 11, 10, 9, and 8 did not result in selective analogs, with the exception of position 11, which markedly decreased affinity/potency. N-Terminal truncations or position 12 substitutions did not increase selectivity as previously reported by others. Of the four shortened analogs of [d-Phe(6),betaAla(11),Phe(13),Nle(14)]Bn(6-14) reported to be potent selective BRS-3 ligands on [Ca(2+)](i) assays, only AcPhe,Trp,Ala,His(tauBzl),Nip,Gly,Arg-NH(2) had moderate selectivity for hBRS-3; however, it was less selective than previously reported Apa(11) analogs, demonstrating these are still the most selective BRS-3 analogs available. However, both of these analogs should be useful templates to develop more selective BRS-3 ligands.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16943256     DOI: 10.1124/jpet.106.107011

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  12 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

Review 2.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 3.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

4.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

5.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

6.  Bombesin receptor subtype-3 agonists stimulate the growth of lung cancer cells and increase EGF receptor tyrosine phosphorylation.

Authors:  Terry W Moody; Veronica Sancho; Alessia di Florio; Bernardo Nuche-Berenguer; Samuel Mantey; Robert T Jensen
Journal:  Peptides       Date:  2011-06-25       Impact factor: 3.750

7.  Molecular basis for agonist selectivity and activation of the orphan bombesin receptor subtype 3 receptor.

Authors:  Nieves Gonzalez; Simon J Hocart; Sergio Portal-Nuñez; Samuel A Mantey; Tomoo Nakagawa; Enrique Zudaire; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2007-11-15       Impact factor: 4.030

8.  Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors.

Authors:  Paola Moreno; Samuel A Mantey; Bernardo Nuche-Berenguer; Marc L Reitman; Nieves González; David H Coy; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2013-07-26       Impact factor: 4.030

9.  Novel chiral-diazepines function as specific, selective receptor agonists with variable coupling and species variability in human, mouse and rat BRS-3 receptor cells.

Authors:  Irene Ramos-Álvarez; Taichi Nakamura; Samuel A Mantey; Paola Moreno; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Peptides       Date:  2015-10-31       Impact factor: 3.750

Review 10.  Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states.

Authors:  Nieves Gonzalez; Terry W Moody; Hisato Igarashi; Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2008-02       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.